Cybrexa Therapeutics

Cybrexa Therapeutics is a private, clinical-stage biotech pioneering an antigen-agnostic approach to targeted cancer therapy via its alphalex™ peptide-drug conjugate platform. The platform exploits the acidic tumor microenvironment to selectively deliver highly potent cytotoxic payloads directly into tumor cells, aiming to overcome limitations of antibody-drug conjugates (ADCs) like antigen dependency and associated toxicities. The company's lead asset, CBX-12, is in Phase 2 for platinum-resistant ovarian cancer, with a broader pipeline in preclinical development. Cybrexa represents a compelling player in the next wave of targeted oncology therapeutics, with the potential to address a wide range of solid tumors.

alphalex™, an antigen-independent peptide-drug conjugate (PDC) platform that uses a pH-Low Insertion Peptide (pHLIP) to exploit the acidic tumor microenvironment for targeted intracellular delivery of cytotoxic payloads.

Cybrexa competes in the targeted oncology drug delivery space, primarily against antibody-drug conjugates (ADCs) from large pharma and other biotechs. Its key differentiation is antigen-independence, positioning it against companies developing other tumor-microenvironment targeting approaches (e.g., pH-sensitive polymers, other peptide platforms). It also faces competition from next-generation ADCs with novel payloads and targeting strategies.